We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

40 hedge funds and large institutions have $10.9M invested in Titan Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

24,433% more call options, than puts

Call options by funds: $736K | Put options by funds: $3K

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0% less ownership

Funds ownership: 0% → 0% (-0%)

15% less funds holding

Funds holding: 47 → 40 (-7)

23% less capital invested

Capital invested by funds: $14.1M → $10.9M (-$3.25M)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

Holders
40
Holders Change
-7
Holders Change %
-14.89%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
7
Reduced
6
Closed
11
Calls
$736K
Puts
$3K
Net Calls
+$733K
Net Calls Change
-$369K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.14M
2
Renaissance Technologies
Renaissance Technologies
New York
+$352K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$70.3K
4
SG Americas Securities
SG Americas Securities
New York
+$56.3K
5
Northern Trust
Northern Trust
Illinois
+$42.2K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$394K
2
GCP
GSA Capital Partners
United Kingdom
-$260K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$197K
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$186K
5
AIM
Acrospire Investment Management
Illinois
-$98.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$2.65M +$3.14M +223 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.33M +$70.3K +5 +3%
State Street
3
State Street
Massachusetts
$963K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$781K +$352K +25 +61%
Northern Trust
5
Northern Trust
Illinois
$678K +$42.2K +3 +6%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$402K – – –
SO
7
STRS Ohio
Ohio
$354K – – –
Goldman Sachs
8
Goldman Sachs
New York
$333K -$14.1K -1 -3%
Morgan Stanley
9
Morgan Stanley
New York
$225K -$394K -28 -60%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$206K – – –
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$197K – – –
TCIM
12
TIAA CREF Investment Management
New York
$180K -$14.1K -1 -6%
Bank of America
13
Bank of America
North Carolina
$140K +$14.1K +1 +9%
California State Teachers Retirement System (CalSTRS)
14
California State Teachers Retirement System (CalSTRS)
California
$128K – – –
TA
15
Teachers Advisors
New York
$120K +$28.1K +2 +25%
AllianceBernstein
16
AllianceBernstein
Tennessee
$102K – – –
Charles Schwab
17
Charles Schwab
California
$100K – – –
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$93K – – –
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$84K – – –
AIM
20
Acrospire Investment Management
Illinois
$75K -$98.4K -7 -54%
RHBC
21
R.H. Bluestein & Co
Michigan
$73K – – –
Deutsche Bank
22
Deutsche Bank
Germany
$72K +$14.1K +1 +20%
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$69K +$28.1K +2 +50%
New York State Common Retirement Fund
24
New York State Common Retirement Fund
New York
$64K – – –
Stifel Financial
25
Stifel Financial
Missouri
$62K -$56.3K -4 -44%
1
2 3

TTNP Hedge Fund Activity: Q1 2017 in Review

40 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2017, worth a combined $10.9M — down 23% from $14.1M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of TTNP and 8 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was BlackRock, opening a new position worth an estimated $3.14M. The largest seller was Morgan Stanley, cutting an estimated $394K.

  • 40 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2017, down from 47 in Q4 2016.
  • Funds reported $10.9M of Titan Pharmaceuticals stock for Q1 2017, down 23% quarter-over-quarter.
  • 8 funds opened new Titan Pharmaceuticals positions in Q1 2017 and 11 closed out, a net change of -3 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $3.14M added.
  • The largest Titan Pharmaceuticals seller in Q1 2017 was Morgan Stanley, an estimated $394K sold.

Based on aggregated 13F filings for Q1 2017.